Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment

Acute myeloid leukemia (AML) is a heterogeneous clonal myeloid neoplasm where abnormal proliferation and impaired differentiation of hematopoietic stem and myeloid progenitor cells impedes normal hematopoiesis. Sulfasalazine (SSZ) is a broadly available, well tolerated anti-inflammatory medicine approved for the treatment of ulcerative colitis and rheumatoid arthritis. Intact SSZ, but not its metabolites 5-aminosalicylic acid and sulfapyridine, competitively inhibits xCT.21 SSZ is thus an ideal candidate for drug repurposing in AML.The purpose of this phase I study is to evaluate the safety an

Trial Details

NCT ID
NCT05580861
Phase
PHASE1 / PHASE2
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Sulfasalazine
Locations (sample)
  • Amiens, France|49.9,2.3
  • Bobigny, France|48.90982,2.45012
  • Caen, France|49.18585,-0.35912
  • Créteil, France|48.79266,2.46569
  • Lyon, France|45.74906,4.84789

Key Eligibility Criteria

  • Patients aged 60 years or older
  • With newly diagnosed acute myeloid leukemia (AML) (short course treatment with hydroxyurea and or steroids is acceptable). Patients with AML second…
  • Eligible for intensive chemotherapy in the investigator's opinion
  • Leukaemia-associated immunophenotypes (LAIP) detected at screening allowing flow cytometry (FCM)-based Minimal Residual Disease monitoring (Phase I…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →